Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Johnson & Johnson Wins EU Nod for ACUVUE OASYS MAX 2-Week Contact Lens
3+ day, 22+ hour ago (299+ words) Medical Product Outsourcing Johnson & Johnson Wins EU Nod for ACUVUE OASYS MAX 2-Week Contact Lens The lenses were engineered to offer clear vision for screen use, outdoor activities, and nighttime driving. Johnson & Johnson has earned CE mark clearance for its…...
SGP: Phase III drug-eluting lens targets cataract and glaucoma, with four-year data and new CPT code — TradingView News
3+ day, 19+ hour ago (93+ words) SGP: Phase III drug-eluting lens targets cataract and glaucoma, with four-year data and new CPT code tradingview.com SGP: Phase III drug-eluting lens targets cataract and glaucoma, with four-year data and new CPT code A novel drug-eluting intraocular lens for…...
Flex eyes healthcare investment after planned spinoff
3+ day, 23+ hour ago (53+ words) Plastics News Flex eyes healthcare investment after planned spinoff North American resin markets have swung sharply back in buyers' favorâPolymer Points explains why prices are falling, what it means for virgin and recycled resins, and whether producers can make…...
SCASTA FAMILY EYECARE AND DENTISTRY
4+ day, 7+ hour ago (54+ words) Bryan College Station Eagle Javascript is required to use this website. Details for SCASTA FAMILY EYECARE AND DENTISTRY LIBERTY HEARING CENTER PLLC FUSION AV OF TEXAS © Copyright 2026 The Eagle, 1729 Briarcrest Drive Bryan, TX 77802 A Lee Enterprises, Incorporated newspaper. Majority…...
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
4+ day, 18+ hour ago (340+ words) Shares of Opus Genetics (IRD) surged more than 30% on Wednesday, clocking its best-ever single-day gains, after the company said that a low dose of its experimental gene therapy showed meaningful improvements in visual function in patients suffering from retinal diseases....
Protecting Competition in Eye Care
4+ day, 20+ hour ago (636+ words) Progressive Policy Institute Protecting Competition in Eye Care In the U.S. health care system, patients are often too far removed from the payment for specific services, which results in a lack of price transparency and consumer choice. However, there are pockets…...
Historic Act of God Coming in September – Bo Polny
5+ day, 8+ hour ago (142+ words) Polny says, “Money creation out of thin air creates an enslavement society.... Remember, in the Bible, God says, ‘The silver is mine and the gold is mine.” Polny goes on to predict, “The charts say the stock market and the…...
Prescient Therapeutics: what has changed since the last PTX100 CTCL update
5+ day, 21+ hour ago (173+ words) Small Caps speaks with Prescient Therapeutics (ASX: PTX) for a general company update focused on what has changed since our last interview on PTX100 in cutaneous T-cell lymphoma (CTCL). Management discusses the most important recent developments, what has or has not…...
TIGIT Inhibitors Clinical Trial Pipeline Gains Momentum: 14+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
6+ day, 15+ min ago (65+ words) TIGIT Inhibitors Clinical Trial Pipeline Gains Momentum: 14+ openPR.com TIGIT Inhibitors Clinical Trial Pipeline Gains Momentum: 14+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight Press release from: DelveInsight Business Research LLP Permanent link to this press release: You can…...
Roivant’s experimental lung disease drug meets goals in mid-stage study
6+ day, 1+ hour ago (262+ words) Sept 8 (Reuters) – Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading. Roivant has been…...